Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Hoffmann

Showing results (91-100 of 113) with videos related to

Pageof 12
Sort By:
Cancer Treatment Reviews|October 20, 2023
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapyNadia Harbeck, Ronald Kates, Timo Schinköthe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2021
Determining the axillary nodal status with four current imaging modalities including <sup>18</sup>F-FDG PET/MRI in newly diagnosed breast cancer: A comparative study using histopathology as reference standardJanna Morawitz, Nils-Martin Bruckmann, Frederic Dietzel, et al.
Frontiers in Medicine|August 29, 2022
Rationale and design of the prevention of paclitaxel-related neurological side effects with lithium trial - Protocol of a multicenter, randomized, double-blind, placebo- controlled proof-of-concept phase-2 clinical trialPetra Huehnchen, Nikola Bangemann, Sandra Lischewski, et al.
Cancers|February 13, 2025
Eribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE StudyMarcus Schmidt, Tobias Hesse, Oliver Hoffmann, et al.
European Radiology|April 29, 2021
Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patientsNils Martin Bruckmann, Julian Kirchner, Lale Umutlu, et al.
AIDS Research and Human Retroviruses|November 15, 2016
HIV-1 Genetic Diversity Among Incident Infections in Mbeya, TanzaniaErik Billings, Eric Sanders-Buell, Meera Bose, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 26, 2020
Prospective evaluation of whole-body MRI and <sup>18</sup>F-FDG PET/MRI in N and M staging of primary breast cancer patientsNils Martin Bruckmann, Lino M Sawicki, Julian Kirchner, et al.
The Oncologist|August 9, 2023
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort StudyHans-Joachim Lück, Marcus Schmidt, Tobias Hesse, et al.
Cancers|July 29, 2023
Conventional Imaging, MRI and <sup>18</sup>F-FDG PET/MRI for N and M Staging in Patients with Newly Diagnosed Breast CancerJanna Morawitz, Nils-Martin Bruckmann, Kai Jannusch, et al.
European Journal of Radiology|May 7, 2020
Impact of <sup>18</sup>F-FDG PET/MR on therapeutic management in high risk primary breast cancer patients - A prospective evaluation of staging algorithmsJulian Kirchner, Ole Martin, Lale Umutlu, et al.
Pageof 12

Showing results (91-100 of 113) with videos related to

Sort By:
Pageof 12
Cancer Treatment Reviews|October 20, 2023
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapyNadia Harbeck, Ronald Kates, Timo Schinköthe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2021
Determining the axillary nodal status with four current imaging modalities including <sup>18</sup>F-FDG PET/MRI in newly diagnosed breast cancer: A comparative study using histopathology as reference standardJanna Morawitz, Nils-Martin Bruckmann, Frederic Dietzel, et al.
Frontiers in Medicine|August 29, 2022
Rationale and design of the prevention of paclitaxel-related neurological side effects with lithium trial - Protocol of a multicenter, randomized, double-blind, placebo- controlled proof-of-concept phase-2 clinical trialPetra Huehnchen, Nikola Bangemann, Sandra Lischewski, et al.
Cancers|February 13, 2025
Eribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE StudyMarcus Schmidt, Tobias Hesse, Oliver Hoffmann, et al.
European Radiology|April 29, 2021
Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patientsNils Martin Bruckmann, Julian Kirchner, Lale Umutlu, et al.
AIDS Research and Human Retroviruses|November 15, 2016
HIV-1 Genetic Diversity Among Incident Infections in Mbeya, TanzaniaErik Billings, Eric Sanders-Buell, Meera Bose, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 26, 2020
Prospective evaluation of whole-body MRI and <sup>18</sup>F-FDG PET/MRI in N and M staging of primary breast cancer patientsNils Martin Bruckmann, Lino M Sawicki, Julian Kirchner, et al.
The Oncologist|August 9, 2023
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort StudyHans-Joachim Lück, Marcus Schmidt, Tobias Hesse, et al.
Cancers|July 29, 2023
Conventional Imaging, MRI and <sup>18</sup>F-FDG PET/MRI for N and M Staging in Patients with Newly Diagnosed Breast CancerJanna Morawitz, Nils-Martin Bruckmann, Kai Jannusch, et al.
European Journal of Radiology|May 7, 2020
Impact of <sup>18</sup>F-FDG PET/MR on therapeutic management in high risk primary breast cancer patients - A prospective evaluation of staging algorithmsJulian Kirchner, Ole Martin, Lale Umutlu, et al.
Pageof 12